Welcome to our dedicated page for Omnicell Com news (Ticker: OMCL), a resource for investors and traders seeking the latest updates and insights on Omnicell Com stock.
Omnicell, Inc. (NASDAQ: OMCL) develops healthcare technology for autonomous medication management across pharmacy and nursing care settings. Its updates cover financial results, product bookings, recurring revenue, connected-device demand, and product launches such as Omnicell Titan XT and the OmniSphere platform.
Company news also includes healthcare conference presentations, customer engagement programs, clinical leadership roles, and innovation updates tied to automation, AI-enabled intelligence, software workflows, data analytics, and expert services for medication management in healthcare facilities.
Omnicell (Nasdaq:OMCL) announced it will present at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 12:45 p.m. EDT in Fort Worth, Texas. Live and archived webcasts of the presentation will be accessible via the Omnicell investor relations website.
EnlivenHealth, a subsidiary of Omnicell (NASDAQ: OMCL), launched VaxReach, a proactive vaccine outreach program designed to help pharmacies identify vaccination-eligible patients and automatically contact them via voice and SMS with educational messages and prompts. The solution will be showcased at ThoughtSpot 2026 as pharmacies prepare for the 2026-27 respiratory and flu season.
According to EnlivenHealth, internal modeling suggests VaxReach may help pharmacies increase monthly vaccinations by up to 66%, assuming a 5% vaccination rate among identified eligible patients, although outcomes are not guaranteed. Key features include automated patient identification using prescription and eligibility data, multichannel outreach, personalized reminders for series completion and boosters, turnkey deployment with centralized campaign visibility, and optional add-ons such as patient self-scheduling, appointment management, registry reporting, and digital pre-visit forms.
Omnicell (NASDAQ: OMCL) reported second quarter 2026 revenues of $312 million, up 7% year over year, driven by connected devices, SaaS, Expert Services, and technical services. GAAP net income rose to $24 million ($0.52 per diluted share) from $6 million, while non-GAAP net income increased to $44 million ($0.94 per diluted share) from $21 million. Non-GAAP EBITDA reached $67 million, compared with $38 million a year earlier. Results benefited from a $15 million refund of previously paid IEEPA tariffs, which reduced cost of revenues and boosted profit and cash flow.
As of June 30, 2026, Omnicell held $292 million in cash and cash equivalents, total debt of $168 million, and generated $68 million in operating cash flow versus $43 million in the prior-year quarter, with $350 million available under its revolver. The company named Nnamdi Njoku President and Chief Operating Officer, added two senior pharmacy-focused executives, and tightened full-year 2026 revenue guidance to $1.225–$1.245 billion. Omnicell raised its 2026 non-GAAP EBITDA outlook to $175–$185 million and non-GAAP EPS to $2.15–$2.30, updated product bookings guidance to $425–$560 million, and set annual recurring revenue guidance at $660–$680 million. Third quarter 2026 guidance includes revenues of $301–$307 million, non-GAAP EBITDA of $32–$37 million, and non-GAAP EPS of $0.35–$0.43.
Omnicell (Nasdaq: OMCL) will release its second quarter 2026 financial results before the market opens on Thursday, July 30, 2026. Management will discuss the results on a conference call and webcast at 8:30 a.m. ET, accessible via U.S. and international dial-in numbers and through the Investor Relations section of Omnicell’s website.
Omnicell (NASDAQ:OMCL) appointed Nnamdi Njoku as President, effective July 1, 2026, while he continues as COO. Randall Lipps remains CEO and Chairman.
Njoku will drive long-term growth strategy, global operations, and key initiatives, including the Omnicell Titan XT system and cloud-native OmniSphere platform.
Omnicell (NASDAQ:OMCL) appointed Dan Mandoli as Senior Vice President and General Manager, Specialty Pharmacy Services. Mandoli brings 30+ years of leadership in specialty pharmacy and pharmacy operations.
His role focuses on scaling Omnicell’s Specialty Pharmacy and 340B businesses, which Omnicell views as key growth drivers.
Omnicell (Nasdaq:OMCL) will present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Tuesday, June 9, 2026, at 3:20 PM EDT.
Live and archived webcasts of the presentation will be available on Omnicell's investor relations website.
Omnicell (Nasdaq:OMCL) will present at the BofA Securities 2026 Healthcare Conference on Tuesday, May 12, 2026 at 8:40 a.m. PDT. Live and archived webcasts will be available on Omnicell's investor website for access by investors and analysts.
Omnicell (NASDAQ:OMCL) appointed Rick Couldry as Senior Vice President, Chief Pharmacy and Clinical Officer, a newly created role aimed at bringing health system pharmacy leadership perspective to Omnicell’s innovation roadmap and portfolio decisions. Couldry has 30 years of hospital pharmacy leadership experience and joins from The University of Kansas Health System.
His responsibilities include informing clinical guidance, shaping thought leadership, and aligning solutions to clinical and operational needs across complex care environments.
Omnicell (NASDAQ:OMCL) reported Q1 2026 results with total revenues of $310 million, up 15% year-over-year, GAAP net income of $11 million ($0.25 diluted EPS) and non-GAAP net income of $25 million ($0.55 diluted EPS). Non-GAAP EBITDA was $45 million. Cash and equivalents totaled $239 million, with $350 million available on the revolving credit facility. The company raised full-year 2026 non-GAAP EBITDA guidance to $153M–$168M and non-GAAP EPS to $1.80–$2.00. Customer engagement began for Omnicell Titan XT and OmniSphere.